Abstract:Objective: Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a subset of IHs, which develop complications resulting in ulceration, bleeding, or aesthetic deformity. The primary treatment for this subset of IHs is pharmacological intervention, and propranolol has become the new first-line treatment for complicated hemangiomas. Here, we evaluated the efficacy of propranolol on proliferation IH in a clinical cohort including 578 patients.Methods: We retrospectively reviewed a total of 578 IH patients who were treated with oral propranolol from January 2010 to December 2012. Responses to the propranolol treatment were graded as: excellent, good, poor, or no response. Based on the response to propranolol treatment (once daily at a dose of 1.0 mg/kg for patients younger than 2 months; twice daily at daily total dose of 2 mg/kg for patients older than 2 months), additional pharmacotherapies or surgery were used for IH patients for satisfactory clinical outcome.Results: Five hundred and sixty (96.9%) of 578 IH patients in our study responded to oral propranolol treatment, and the response rate was significantly different for different ages of patients (P<0.05), with the youngest patients having the highest response rate. The mean time of treatment was 6 months (range, 3-12 months). For example, response rate to propranolol was 98.1% in patients younger than 2 months, compared with 93.3% in patients older than 2 months and younger than 8 months, and 73.7% in patients older than 8 months. One hundred and thirty one patients who exhibited incompletely involuted hemangiomas were further treated with timolol maleate (n=89) or pulsed dye laser (n=42). One hundred and seventeen (89.3%) of 131 patients showed a positive response. There were no instances of life-threatening complications after propranolol. However, minor side effects were observed including 10 (1.73%) cases of sleep disturbance, 7 (1.21%) cases of diarrhea, and 5 (0.86%) cases of bronchospasm.Conclusion: IH requires early intervention. During the involution phase, tapering propranolol dosage can be done to minimize side effects before discontinuing treatment. For patients exhibiting telangiectasia and chromatosis after propranolol treatment, administration of a 0.5% solution of timolol maleate or pulse dye laser is an effective therapeutic approach for complete involution.

Lip Infantile Hemangiomas Involving the Vermillion Border Have Worse Outcomes and Prognosis to Oral Propranolol Than Lesions Confined to One Side of the Vermillion.

Intralesional Betamethasone Versus Oral Propranolol for Localized Infantile Hemangiomas of the Lip.

Distribution of Problematic Localized Facial Infantile Haemangiomas and Their Response to Propranolol: a Retrospective Cohort Study

Timing and Safety of Oral Propranolol for Infantile Hemangioma

Does Oral Propranolol Improve the Final Outcome of All Involuted Infantile Hemangiomas? A Matched Retrospective Comparative Study

Clinical and Radiological Outcomes of Infantile Hemangioma Treated with Oral Propranolol: A Long‐term Follow‐up Study

Practical surgical technique using the SMISS approach for lip reduction in involuted lip infantile hemangiomas

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Oral Propranolol Combined with Topical Timolol for Compound Infantile Hemangiomas: Results in 89 Consecutive Patients

A 7-Year Follow-Up Study on Untreated Deep or Mixed Facial Infantile Hemangioma in East-Asian Patients: when Propranolol Was Not Yet an Option

Comparison of Oral Propranolol Alone and Combined with Topical 0.5 ％ Timolol Maleate Cream for the Treatment of Infantile Hemangiomas

Clinical Features of Cutaneous Infantile Hemangioma Combined with Asymptomatic Infantile Hepatic Hemangioma and Efficacy of Propranolol Treatment.

Propranolol Therapy for Infantile Hemangioma: Our Experience

Location of infantile hemangioma is a predictor of volumetric sequelae after involution.

Comparison of efficacy and safety between oral propranolol combined with and without intralesional injection of lauromacrogol for infantile hemangioma

Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients.

Effectiveness And Safety Of Oral Propranolol Versus Other Treatments For Infantile Hemangiomas: A Meta-Analysis

[Chinese Experts Consensus on the Use of Oral Propranolol for Treatment of Infantile Hemangiomas].

Efficacy and Safety of Oral Propranolol or Topical Timolol for the Treatment of Superficial Infantile Hemangiomas

A Survey on Clinical Use of Propranolol for Infantile Hemangiomas in Mainland China.

The Efficacy and Safety of Treatments for Infantile Hemangiomas: a Bayesian Network Meta‐analysis